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Objective. To evaluate leptin and adiponectin as biomarkers of metabolic syndrome (MS) risk factors even in nonobese
children/adolescents. Methods. Serum leptin, adiponectin, leptin:adiponectin ratio, lipids, glucose, and insulin concentrations
as well as body size parameters and pubertal development were evaluated in a large population of Chinese children/adolescents
(n = 3505,6–18years,1722girlsand1783boys).Results.Leptinconcentrationincreasedwhileadiponectindecreasedwithobesity,
both were inﬂuenced by pubertal development. Central obesity had an additive eﬀect on leptin levels (above obesity alone).
Leptin/adiponectin increased 8.4-fold and 3.2-fold in overweight/obesity, and 15.8- and 4.5-fold with obesity plus MS, in early
and late puberty, respectively. Even in normal weight children/adolescents, higher leptin and lower adiponectin concentrations
associated with increased risk proﬁle. Conversely, overweight/obese with lower leptin or higher adiponectin concentrations had a
less compromised metabolic proﬁle. Conclusion. Leptin, adiponectin, and leptin:adiponectin ratio are informative biomarkers for
obesity, central obesity, MS, and abnormal metabolic proﬁle even in normal weight children/adolescents.
1.Introduction
The alarming increase in obesity worldwide is of concern,
due to the associations of obesity with metabolic syndrome
(MS), insulin resistance, Type 2 diabetes, dyslipidaemia and
cardiovascular disease [1, 2]. This increase is noted even in
populations previously at reduced risk, such as Asia [3], even
inchildren[4].MSischaracterizedbycentralobesity,insulin
resistance, hyperglycaemia, dyslipidaemia (increased triglyc-
eride and decreased HDL), and hypertension; all risk factors
forcardiovasculardiseaseandType2diabetesmellitus.Char-
acterization of MS potentially identiﬁes individuals predis-
posedtocardiovasculardiseaseandType2diabetes,allowing
measures to be instituted early-on [3]. Adult urban versus
rural populations are at higher MS risk [5]a n dp r e v a l e n c e
varies with gender, age, ethnic background, and residence
[1, 5]. Puberty, with naturally occurring growth spurts and
hormonal changes coupled to behavioural changes, is a
critical period for development of obesity and childhood MS
[6]. Further, the associated pathological processes and risk
factors have been observed in obese children and adolescents
[7–9].
Adipose tissue secretes adipokines inﬂuencing body
weight, glucose, and lipid metabolism [7]. Adiponectin, a
collagen-like protein exclusively expressed in adipose tissue,
has antiatherogenic, antidiabetic and anti-inﬂammatory
properties [10–12]. Increased adiponectin is associated
with a lower risk of impaired glucose tolerance, decreased
myocardial infarction risk, and has been proposed as a
biomarker of early atherosclerosis [10, 11, 13]. Adiponectin
decreasesinobesityandrelateddiseases,andmaybeinvolved2 Journal of Obesity
Table 1: Anthropometric and metabolic parameters in girls and boys. Data are expressed as mean ± SD where ∗∗P<. 01 and ∗∗∗P<. 001.
For Tanner, the number (percentage) of participants is presented with χ2 test. #Skewed distributions were logarithmically transformed for
t-test.
Variables All Girls Boys
n 3505 1722 1783
Age (years) 12.4 ±3.11 2 .6 ±3.1
∗∗∗ 12.2 ±3.0
Pubertal development 3388 1693 1695
Tanner stage I 1001(29.5) 336(19.8) 665(39.2)
Tanner stage II 486(14.3) 216(12.8) 270(15.9)
Tanner stage III 464(13.7) 208(12.3) 256(15.1)
Tanner stage IV 813(24.0) 610(36.0) 203(12.0)
Tanner stage V 624(18.4) 323(19.1)
∗∗∗ 301(17.8)
Leptin (ng/ml)# 10.0 ±11.41 1 .0 ±11.6
∗∗∗ 9.1 ± 11.2
Adiponectin (μg/ml)# 12.8 ±7.41 3 .2 ±7.2
∗∗∗ 12.3 ±7.6
Ratio leptin/adiponectin# 1.24 ±1.90 1.33 ±2.10
∗∗∗ 1.15 ±1.68
Body mass index (kg/m2)2 1 .9 ±4.92 1 .0 ±4.5
∗∗∗ 22.8 ±5.2
Waist circumference (cm) 72.4 ±13.16 8 .6 ±10.8
∗∗∗ 76.0 ±14.0
Waist to height ratio 0.47 ±0.07 0.46 ±0.06
∗∗∗ 0.49 ±0.07
Fat mass percentage (%) 24.4 ±8.52 5 .6 ±9.0
∗∗∗ 23.2 ±7.8
Systolic BP (mmHg) 107.6 ±13.9 104.7 ±12.3
∗∗∗ 110.4 ±14.8
Diastolic BP (mmHg) 67.8 ±10.06 6 .8 ±9.4
∗∗∗ 68.8 ±10.5
Triglycerides (mmol/l)# 1.03 ±0.56 1.03 ±0.55 1.02 ±0.57
Total cholesterol (mmol/l) 4.09 ±0.79 4.11 ±0.81 4.07 ±0.78
HDL-C (mmol/l) 1.40 ±0.32 1.42 ±0.30
∗∗ 1.39 ±0.34
LDL cholesterol (mmol/l) 2.54 ±0.72 2.56 ±0.74 2.53 ±0.71
Glucose (mmol/l) 5.10 ±0.62 5.03 ±0.67
∗∗∗ 5.15 ±0.55
Insulin (mU/l)# 10.46 ±9.95 10.18 ±8.92 10.72 ±10.84
HOMA-IR# 2.43 ±2.62 2.33 ±2.29 2.52 ±2.90
Table 2: Pearson correlation coeﬃcients of leptin and adiponectin. #Skewed distributions logarithmically transformed for Pearson
correlation. Signiﬁcances are ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001.
Variables
Leptin# Adiponectin#
Girls Boys Girls Boys
NonOwt Owt/Ob NonOwt Owt/Ob NonOwt Owt/Ob NonOwt Owt/Ob
n 963 722 680 1064 986 725 708 1066
Age 0.517
∗∗∗ 0.253
∗∗∗ 0.033 −0.172
∗∗∗ −0.191
∗∗∗ −0.201
∗∗∗ −0.350
∗∗∗ −0.366
∗∗∗
Leptin# —— —— −0.219
∗∗∗ −0.097
∗∗ −0.114
∗∗ 0.018
Adiponectin# −0.219
∗∗∗ −0.097
∗∗ −0.114
∗∗ 0.018 — — — —
Body mass index 0.691
∗∗∗ 0.469
∗∗∗ 0.377
∗∗∗ 0.272
∗∗∗ −0.282
∗∗∗ −0.240
∗∗∗ −0.301
∗∗∗ −0.329
∗∗∗
Waist circumference 0.708
∗∗∗ 0.466
∗∗∗ 0.351
∗∗∗ 0.291
∗∗∗ −0.267
∗∗∗ −0.288
∗∗∗ −0.329
∗∗∗ −0.346
∗∗∗
Waist to height ratio 0.375
∗∗∗ 0.354
∗∗∗ 0.432
∗∗∗ 0.466
∗∗∗ −0.180
∗∗∗ −0.141
∗∗∗ NS −0.082
∗∗
Fat mass percentage 0.734
∗∗∗ 0.498
∗∗∗ 0.446
∗∗∗ 0.386
∗∗∗ −0.271
∗∗∗ −0.230
∗∗∗ −0.157
∗∗∗ NS
Systolic BP 0.294
∗∗∗ 0.150
∗∗∗ NS NS −0.173
∗∗∗ −0.109
∗∗ −0.202
∗∗∗ −0.225
∗∗∗
Diastolic BP 0.274
∗∗∗ 0.133
∗∗∗ NS NS −0.108
∗∗∗ NS −0.099
∗∗ −0.126
∗∗∗
Triglycerides# 0.342
∗∗∗ 0.218
∗∗∗ 0.281
∗∗∗ 0.272
∗∗∗ −0.144
∗∗∗ −0.172
∗∗∗ −0.109
∗∗ −0.144
∗∗∗
Total cholesterol NS NS 0.140
∗∗∗ 0.154
∗∗∗ NS NS NS NS
HDL-C −0.193
∗∗∗ NS −0.088 NS 0.246
∗∗∗ 0.231
∗∗∗ 0.231
∗∗∗ 0.326
∗∗∗
LDL cholesterol NS NS 0.153
∗∗∗ 0.153
∗∗∗ NS NS NS NS
Glucose 0.121
∗∗∗ NS NS NS NS NS NS 0.068
Insulin# 0.510
∗∗∗ 0.425
∗∗∗ 0.366
∗∗∗ 0.339
∗∗∗ −0.201
∗∗∗ −0.211
∗∗∗ −0.201
∗∗∗ −0.270
∗∗∗
HOMA-IR# 0.502
∗∗∗ 0.409
∗∗∗ 0.364
∗∗∗ 0.326
∗∗∗ −0.200
∗∗∗ −0.197
∗∗∗ −0.196
∗∗∗ −0.247
∗∗∗Journal of Obesity 3
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in cardiovascular disease and Type 2 diabetes mellitus
pathology [14].
Leptin, a cytokine-like molecule secreted by adipose
tissue, regulates adipose mass and body weight by inhibiting
food intake and stimulating energy expenditure [15, 16].
Leptin increases in obesity, Type 2 diabetes mellitus, hyper-
tension and MS. Numerous publications in adults suggest
leptin as a biomarker for obesity, insulin resistance, and MS
[15, 16].
Obesity, MS prevalence and associated risk factors in
children and adolescents have increased dramatically over
decades [4, 8], including in Chinese populations [1, 2, 17,
18]. This relationship is diﬃcult to evaluate as obesity-
induced acute insulin resistance is usually identiﬁed later,
and many changes are associated with pubertal and socioe-
conomic changes [6, 19, 20]. Leptin and adiponectin are
proposed as biomarkers in children for predicting MS, Type
2 diabetes, or cardiovascular disease [21]; however, the
lack of deﬁned cutoﬀ markers complicates this [22]. Many
studies on leptin and/or adiponectin in children [12, 23–25],
includingAsianchildren[5,26,27],suﬀerfromsmallsample
sizes, with only two studies over 800–1000 children, limiting
subgroup analysis.
Recently, leptin-to-adiponectin ratio was proposed as a
biomarker with the beneﬁts of both indices [28–30] included
in Chinese adults [5]. In Hispanic youth [31] leptin-to-
adiponectin ratio provided an independent predictor of
insulin sensitivity during growth [31].
In this study, we evaluated adipokines, anthropometric,
and lipid parameters in a large study of 3505 Chinese
children and adolescents aged 6–18 years old. We demon-
strate that even in normal weight children and adolescents,
leptin and adiponectin are informative biomarkers of risk,
and also discriminate between lower versus higher risk in
overweight/obese subjects.
2.Materials/SubjectsandMethods
2.1. Subjects and Samples Collection. Subjects were recruited
from a cross-sectional population-based survey: the Beijing
Child and Adolescent Metabolic Syndrome (BCAMS) study
as described elsewhere [32]. The cohort included 3505
children, 1722 girls, and 1783 boys of normal weight,
overweight, and obese deﬁned by age-gender-speciﬁc BMI
according to the International Obesity Task Force (IOTF)
[33]. Signed informed consent was obtained from partic-
ipants and/or parents/guardians. The BCAMS study was
approved by the Ethics Committee at Capital Institute of
Pediatrics in Beijing. Subjects were evaluated for height,
weight, waist circumference, Tanner stage, and fat mass %
(by bioimpedance analysis).
2.2. Clinical and Metabolic Parameters. Venous blood sam-
ples were collected by direct venipuncture after an overnight
(minimum 12h) fast. The samples were centrifuged, serum
and plasma aliquoted and immediately frozen and main-
tained at −80
◦C for later analysis of lipids and hormones.
Samples were collected and analysed over a two-year period.
Blood samples were analyzed for glucose, triglyceride (TG),
total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C),
insulin, adiponectin, and leptin. Serum lipids (enzymatic
methods)andplasmaglucose(glucoseoxidasemethod)were
assayed using the Hitachi 7060C automatic biochemistry
analysis system. HDL-C and LDL-C were measured directly.
Serum insulin was measured by monoclonal antibody-based
sandwich enzyme-linked immunosorbent assays (ELISA)
[34], developed in Key Laboratory of Endocrinology, Peking
Union Medical College Hospital with interassay CVs of
<9.0% and no cross-reactivity to proinsulin (<0.05%).
Serum adiponectin was measured by ELISA with intra-assay
and interassay coeﬃcients of variation of <5.4% and <8.5%,
respectively, (see details elsewhere) [32]. All antibodies,
reagents and adiponectin standard were purchased from
Phoenix Pharmaceuticals Inc. (Belmont, CA, USA).
Serum leptin was measured by ELISA [35] using rabbit
polyclonal (PAb) and mouse monoclonal (MAb) antihuman
leptin antibodies prepared following injection of human
leptin (R&D System, USA). Plates coated with 3μg/mL PAb
incarbonatebuﬀerwereincubatedovernightat4◦C,blocked
f o r1 hw i t h1 %B S Ai np h o s p h a t e - b u ﬀered saline (PBS).
Standards (50μL, 0–12.5ng/ml, 9 serial dilutions in 1%
BSA-PBS), diluted blood samples and quality controls were
loaded. Biotin-labeled MAb (50uL, diluted 1:1000) were
added and incubated 1.5 hours at 37
◦C. For the following
steps, plates were washed between each step: (i) 100μL
avidin-HRPO(diluted1:1000), 30minutes 37
◦C;(ii)100μL
chromogenic substrate TMB and development solution, 10
minutes 37
◦C; (iii) 100μL1MH 2SO4; (iv) OD at 450nm.
Sensitivity was 0.03ng/ml; range 0.05–5ng/ml, intra-assay
and interassay coeﬃcients of variation were <7.4% and
<9.3%.
2.3. Classiﬁcation of Pediatric Metabolic Syndrome. Pediatric
metabolic syndrome was deﬁned by the presence of three
or more of the following ﬁve components [36]: (i) central
obesitydeﬁnedasage/genderwaistcircumference≥90thper-
centile(establishedbasedon theBCAMSstudy);(ii)elevated
age/gender systolic and/or diastolic blood pressure ≥90th
percentile (BCAMS); (iii) hypertriglyceridemia ≥1.24mM,
(90th percentile referencepopulation); (iv) low-serumHDL-
C < 1.03mM (5th percentile reference population); (v)
impaired fasting glucose ≥5.6mM.
2.4. Calculations and Statistical Analysis. Unless otherwise
stated, results are mean ± standard deviation (SD). BMI
was calculated as weight/height2 (kg/m2). Insulin resis-
tance calculated by homeostasis-model-assessment-insulin-
resistance (HOMA-IR) is (insulin IU-l−1) × (glucose
mmol−1)/22.5. Analyses and graphics were performed using
SysStat,SigmaStatV3.5,andGraphPadPrismV5.0.Allskewed
distributions were log transformed for analysis. T-Test was
used for comparison of two groups. One-way or two-
way ANOVA was used for comparison of multiple groups
(as indicated) with Tukey-Kramer post hoc comparison
being used to evaluate group diﬀerences. Where indicated,6 Journal of Obesity
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Figure 1: Leptin and adiponectin versus body size and central fat. Children were separated according to Tanner (puberty) and body size into
non-overweight (NonOwt), overweight, and obese (Owt/Ob) ± central obesity. Values are reported as leptin for girls (a), and boys (b), and
mean adiponectin for girls (c) and boys (d). One way ANOVA is ∗∗P<. 01, ∗∗∗P<. 001 versus NonOwt, P<. 01, P<. 001 Owt/Ob.
a gender-adjusted general linear model was used in analysis.
Correlations were calculated using Pearson correlation coef-
ﬁcient. Signiﬁcance was set at P<. 01.
3. Results
3.1. Clinical Characteristics of Children and Adolescents. The
baseline characteristics are summarized in Table 1.S u b j e c t s
ranged from 6 to 18 years, distributed across all Tanner
stages, with a mean age of 12.4 ± 3.1 years. Girls had a more
advanced pubertal development than boys. Serum TC, LDL
cholesterol, and insulin levels were not diﬀerent between
girls and boys, while leptin, adiponectin, and the ratio
of leptin/adiponectin as well as body composition indices,
HDL and glucose were diﬀerent. Leptin and adiponectin
correlated with multiple factors in both boys and girls,
including BMI (used to evaluate overweight/obesity), waist
circumference (the measure for central obesity), and factorsJournal of Obesity 7
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Figure 2: Leptin and adiponectin in overweight/obese children/adolescents ± metabolic syndrome (MS) versus non-overweight (NonOwt)
children. Children were separated according to early puberty (Tanner I + II) and late puberty (Tanner stage IV + V) and body size NonOwt
and overweight/obese groups (Owt/Ob) ± MS. Mean ± SD for leptin (a), adiponectin (b) and leptin/adiponectin (c) were analyzed using
general linear model gender-adjusted (P<. 001), where ∗∗P<. 01, ∗∗∗P<. 001 versus NonOwt and P<. 01, P<. 001 versus OWt/Ob
− MS.8 Journal of Obesity
used in MS evaluation (blood pressure, triglyceride, HDL-C
and glucose (data not shown)). Only leptin correlated with
LDL cholesterol. Subjects were separated based on gender
and BMI (normal weight (NonOwt) and overweight/obese
(Owt/Ob). Leptin and adiponectin correlated with body
weight parameters and metabolic indices including TG,
HDL-C, and insulin (Table 2).
3.2.SerumAdiponectinandLeptinLevelsinOverweight/Obese
Subjects with Central Obesity. Children and adolescents
were separated according to Tanner stage, gender and BMI
(NonOwt or Owt/Ob only), and Owt/Ob with central
obesity (Figure 1). In girls, leptin increased with Tanner
stage, while adiponectin decreased. In boys, Tanner-related
leptin changes were less pronounced, while adiponectin
proﬁle was similar to girls. Overall, leptin increased and
adiponectin decreased in Owt/Ob in girls and boys (P<
.001). Interestingly, central obesity had a pronounced eﬀect
on leptin, additional to overweight/obesity, in boys and girls
(all Tanner stages) (Figures 1(a) and 1(b)). By contrast,
central obesity impact on adiponectin was not additive to
overweight/obesity alone, with little change (girls Tanner IV,
boys Tanner I and II) (Figures 1(c) and 1(d)).
3.3. Adiponectin and Leptin Concentrations in Subjects with
Overweight/Obesity with or without MS in Early and Late
Puberty Stages. Children/adolescents grouped into early
puberty (Tanner I/II) and late puberty (Tanner IV/V) were
divided into NonOwt, Owt/Ob – MS, and Owt/Ob + MS.
In early and late puberty, MS had additional eﬀect on
increasing leptin (Figure 2(a)) and decreasing adiponectin
(Figure 2(b)) that was additive to overweight/obesity. Fur-
ther, leptin/adiponectin ratio, which has been proposed
as a biomarker, increased by 8.4- and 3.2-fold in over-
weight/obesity, and by 15.8- and 4.5-fold with MS (Fig-
ure 2(c)). MS was associated with additive eﬀects on waist
circumference, blood pressure, TG, HDL-C, and glucose
(parametersusedtodeﬁneMS),butalsoonotherparameters
(BMI, TC, LDL-C, and insulin) (data not shown). Even in
early puberty (<10 years), overweight/obesity inﬂuenced the
adipokines leptin and adiponectin. Further, central obesity
and MS were additive to overweight/obesity, and even at
this young age, were associated with alterations in leptin,
adiponectin and leptin-to-adiponectin ratio.
3.4. Metabolic Proﬁles in Upper Quintiles and Lower Quintiles
of Leptin in Normal Weight and Overweight/Obese Children
and Adolescents. While average leptin is signiﬁcantly dif-
ferent between NonOwt and overweight/obese individuals,
there is a substantial overlap between the distribution,
s u c ht h a ts o m eN o n O w th a v eh i g hl e p t i na n ds o m eo v e r -
weight/obese individuals have low leptin (comparable to
NonOwt). This raises the question of whether NonOwt
+ high leptin presents a greater metabolic risk, and, con-
versely, whether obese + low leptin have better metabolic
proﬁle. This was evaluated in a gender- and puberty-speciﬁc
manner. Upper quintile (top 20% leptin, Q5) had mean
leptin 10–15-fold greater than lower quintile group (bottom
20% leptin, Q1) (Table 3). Interestingly, separation based
on leptin does not discriminate for adiponectin with Q1
versus Q5 equivalent in NonOwt and overweight/obese. In
NonOwt-Q5, although leptin is increased and within the
overweight/obese range, BMI and WC remained normal.
Finally, while Q5 leptin had no change in blood pressure,
TC, LDL-C, or glucose (versus Q1), TG and insulin were
diﬀerent, suggesting that, separate from weight status, higher
leptin may indicate additional metabolic risk.
3.5. Metabolic Proﬁles in Upper Quintiles and Lower Quintiles
of Adiponectin in Normal Weight and Overweight/Obese
Children and Adolescents. A similar analysis was conducted
for adiponectin. While adiponectin distribution was shifted
to lower values in overweight/obese subjects, there was
substantial overlap, raising the questions: are NonOwt + low
adiponectin at greater metabolic risk? are overweight/obese
+ high adiponectin more protected? In groups separated
based on gender and puberty, upper quintile (Q5) and lower
quintile (Q1) of adiponectin were compared (Table 4). Q5
NonOwt versus overweight/obese were similar regardless
of weight status (same for Q1 groups), while Q5 was
consistently 4-5-fold greater than Q1. Separation-based on
adiponectin is non-discriminatory for leptin, with little
diﬀerence in Q1 versus Q5, NonOwt and overweight/obese
groups. Further, maximal % diﬀerence between Q5 and Q1
for BMI and WC was never greater than 10%. Adiponectin
quintiles did not diﬀerentiate blood pressure, TC, LDL-C, or
glucose, but Q1 adiponectin was generally associated with
higher TG and insulin in NonOwt and overweight/obese
children.
4. Discussion
In Asia, there has been an alarming increase in child-
hood/adolescent obesity, a major determinant of MS devel-
opment [1, 2, 17, 18] a precursor to cardiovascular and
Type 2 diabetes diseases [12, 24, 37], even in Chinese [3].
Adiponectin and leptin are correlated with MS in children
and might be useful as a predictive marker of MS, although
no consensus has been reached on this [12, 23–25, 27].
In the current study, we investigated adiponectin and
leptin as diagnostic biomarkers in >3500 Beijing chil-
dren/adolescents with varying weight and puberty. Lep-
tin was increased and adiponectin decreased in over-
weight/obesity, with adiponectin decreasing with puberty
(boys and girls) and leptin increasing with puberty (girls).
The pubertal eﬀect on these adipokines is consistent with
German,American,andJapanesestudiesinchildren[26,31],
and has been suggested to be related to changes in sex
hormones [19].
Leptin was strongly associated with central obesity, in
contrast to adiponectin. Adiponectin, leptin, and leptin-to-
adiponectin ratio were strongly associated with MS, even at
early puberty. These additive eﬀects were consistent across
puberty, in spite of adiponectin decreases (girls and boys)
and leptin increases (girls only) with puberty.Journal of Obesity 9
The most pertinent ﬁnding is the clustering of risk
factors with increased leptin or decreased adiponectin which
was present in NonOwt groups. NonOwt + high leptin or
NonOwt + low adiponectin children manifested metabolic
perturbations comparable to overweight/obese groups. This
was evident in late, but also notably in early puberty, in
boys and girls. Even in very young children, adipokines (lep-
tin, adiponectin, leptin-to-adiponectin) might be valuable
biomarkers for identifying NonOwt children at risk for later
metabolic issues. However, one limitation of this study is the
cross-sectional nature, and in the absence of a prospective
longitudinal analysis, interpretation of the correlations can
only be inferred.
Previousstudieshavedemonstratedbiomarkerclustering
in overweight/obese children, healthy children and both [12,
38–40], although these studies had only 300–600 subjects,
in comparison to the large number of subjects in the
present study, and did not necessarily cover the same age
range. Interestingly, following lifestyle intervention in obese
children, adiponectin proved to be the most signiﬁcant
predictor of improved metabolic proﬁle, while changes
in leptin were unrelated to positive metabolic outcomes
[37]. Nonetheless, the clustering of multiple unfavourable
biomarkers strongly supports the need for early intervention
not only in childhood obesity, but also in normal weight
subjects that manifest proﬁles at risk.
5. Conclusion
In summary, this large study of Chinese children and ado-
lescents demonstrated leptin and adiponectin associations
with central obesity and MS. Even in obesity, high leptin
and low adiponectin predicts additional metabolic stress.
Importantly, NonOwt with high leptin and low adiponectin
predict an unfavourable metabolic proﬁle regardless of gen-
der/puberty. In future studies, followup of these NonOwt at-
risk children may help to further demonstrate the usefulness
of these biomarkers.
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